Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors-Reference-Cited by-同舟云学术

Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors

Published:2019-09-30 Issue:12 Volume:49 Page:2245-2251
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Creasy Caitlin A.¹,Forget Marie‐Andrée¹,Singh Gopal²,Tapia Coya³,Xu Mingxuan²,Stephen Bettzy²,Sabir Sharjeel⁴,Meric‐Bernstam Funda²,Haymaker Cara³,Bernatchez Chantale¹³^ORCID,Naing Aung²

Affiliation:

1. Department of Melanoma Medical OncologyThe University of Texas MD Anderson Cancer Center (MDACC) Houston TX

2. Department of Investigational TherapeuticsThe University of Texas MDACC Houston TX

3. Department of Translational Molecular PathologyThe University of Texas MDACC Houston TX

4. Department of Interventional RadiologyThe University of Texas MDACC Houston TX

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/eji.201948217

Reference24 articles.

1. Anti-CTLA4 antibody clinical trials in melanoma

2. Cancer immunotherapy using checkpoint blockade

3. CTLA-4 and PD-1 Pathways

4. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current application of immunotherapy in melanoma;Chinese Medical Journal;2023-04-17

2. The current knowledge concerning solid cancer and therapy;Journal of Biochemical and Molecular Toxicology;2021-08-31

3. Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study;Cancers;2021-07-23

4. MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC;European Journal of Immunology;2020-07-09